8 September 2014
Sonendo®, Inc., the developer of a transformative technology for the endodontic marketplace, announced today it has completed an equity financing totaling $35 million. The proceeds from the financing will be used to further technology development, fund clinical studies, and commercialize Sonendo’s GentleWave™ System for root canal therapy. The System debuted at the American Association of Endodontists (AAE) annual meeting in May of this year, and is currently in limited market release.
12 August 2014
JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, today announced that cardiovascular medical device industry veteran Stefan Schreck, Ph.D. has been named the Company’s new chief technology officer, effective immediately.
31 July 2014NeoMed Innovation V, an investment fund exclusively focused on companies developing medical products successfully completed its final closing
NeoMed Management announced that it held a final closing of NeoMed Innovation V L.P. with €92.1 million ($122 million) in committed capital. Investors include the European Investment Fund and a number of returning investors among them Höegh Capital Partners, Argentum and Sedco Capital.
7 July 2014
JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, today announced that medical device industry veteran David J. Drachman has been named the Company’s new chief executive officer, effective immediately.
27 June 2014InDex Pharmaceuticals announces results from COLLECT, a clinical trial of Kappaproct® in the treatment of moderate to severe Ulcerative Colitis
InDex Pharmaceuticals today reported top-line results from the double blind, placebo-controlled clinical study COLLECT. The aim of the COLLECT study was to investigate the therapeutic potential of the Toll-like receptor 9 agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis.